GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Gross Margin %

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Gross Margin % : 66.67% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Chongqing Genrix Biopharmaceutical Co's Gross Profit for the three months ended in Jun. 2024 was ¥0.00 Mil. Chongqing Genrix Biopharmaceutical Co's Revenue for the three months ended in Jun. 2024 was ¥0.01 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's Gross Margin % for the quarter that ended in Jun. 2024 was 66.67%.


The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's Gross Margin % or its related term are showing as below:

SHSE:688443' s Gross Margin % Range Over the Past 10 Years
Min: -11.37   Med: 35.48   Max: 50.49
Current: 40.92


During the past 5 years, the highest Gross Margin % of Chongqing Genrix Biopharmaceutical Co was 50.49%. The lowest was -11.37%. And the median was 35.48%.

SHSE:688443's Gross Margin % is ranked worse than
68.26% of 753 companies
in the Biotechnology industry
Industry Median: 60.8 vs SHSE:688443: 40.92

Chongqing Genrix Biopharmaceutical Co had a gross margin of 66.67% for the quarter that ended in Jun. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Chongqing Genrix Biopharmaceutical Co was 0.00% per year.


Chongqing Genrix Biopharmaceutical Co Gross Margin % Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Gross Margin % Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
35.48 25.18 50.49 -11.37 38.94

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.91 66.67 40.49 66.67 66.67

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Gross Margin %

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Gross Margin % falls into.



Chongqing Genrix Biopharmaceutical Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Chongqing Genrix Biopharmaceutical Co's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0.5 / 1.212
=(Revenue - Cost of Goods Sold) / Revenue
=(1.212 - 0.74) / 1.212
=38.94 %

Chongqing Genrix Biopharmaceutical Co's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=0 / 0.006
=(Revenue - Cost of Goods Sold) / Revenue
=(0.006 - 0.002) / 0.006
=66.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Chongqing Genrix Biopharmaceutical Co had a gross margin of 66.67% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Chongqing Genrix Biopharmaceutical Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines